Dostinex 0,5 mg TABLET
PDF Leaflet Revision Date: 18 November 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Inhibition of lactation and treatment of hyperprolactinaemic disorders.
Dosage (summary)
1 mg as a single dose for inhibition of lactation; 0.5 mg weekly for hyperprolactinaemia.
Onset of Action / Duration
Onset: 3 hours, Duration: 7-28 days
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; monitor pituitary size if pregnancy occurs.
Key Drug Interactions
- Dopamine antagonists
- Macrolide antibiotics
Contraindications
- Hypersensitivity to cabergoline
- Pregnancy
- Hepatic insufficiency
- Cardiac valvulopathy
Common side effects
- Dizziness
- Headache
- Nausea
- Abdominal pain
Counselling Points
- Avoid driving if experiencing somnolence
- Monitor blood pressure
- Use contraception during treatment
Serious warnings
- Postural hypotension
- Fibrotic disorders
- Somnolence
Important Disclaimer
The Dostinex 0,5 mg TABLET professional information leaflet below is the property of Pfizer Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
